View in EDS

TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study.

Saved in:
Bibliographic Details
Title: TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study.
Authors: Yang XG; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Deng LW; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Zhao Y; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China., Peng B; Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China., Liu B; Department of Tumor Vascular Intervention, Chengdu Qingbaijiang District People's Hospital, Chengdu, China., Feng SF; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China., Liu DX; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China., Liu JF; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Sun YY; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Chen Y; Department of pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Liao CL; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Zhang C; Department of Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Liu L; Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China., Cao L; Department of Tumor Vascular Intervention, Chengdu Qingbaijiang District People's Hospital, Chengdu, China. 327511253@qq.com., Ren Y; Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China. ir_cd_2nd_ph@sina.com., Wei G; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China. weiguo69@sohu.com., Xu GH; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China. xgh0913@hotmail.com.
Source: Hepatology international [Hepatol Int] 2026 Apr; Vol. 20 (2), pp. 384-395. Date of Electronic Publication: 2026 Feb 17.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 101304009 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-0541 (Electronic) Linking ISSN: 19360533 NLM ISO Abbreviation: Hepatol Int Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41703369
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yang+XG%22">Yang XG</searchLink>; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Deng+LW%22">Deng LW</searchLink>; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Zhao+Y%22">Zhao Y</searchLink>; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Peng+B%22">Peng B</searchLink>; Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Liu+B%22">Liu B</searchLink>; Department of Tumor Vascular Intervention, Chengdu Qingbaijiang District People's Hospital, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Feng+SF%22">Feng SF</searchLink>; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Liu+DX%22">Liu DX</searchLink>; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Liu+JF%22">Liu JF</searchLink>; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Sun+YY%22">Sun YY</searchLink>; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Chen+Y%22">Chen Y</searchLink>; Department of pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Liao+CL%22">Liao CL</searchLink>; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Zhang+C%22">Zhang C</searchLink>; Department of Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Liu+L%22">Liu L</searchLink>; Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Cao+L%22">Cao L</searchLink>; Department of Tumor Vascular Intervention, Chengdu Qingbaijiang District People's Hospital, Chengdu, China. 327511253@qq.com.<br /><searchLink fieldCode="AU" term="%22Ren+Y%22">Ren Y</searchLink>; Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China. ir_cd_2nd_ph@sina.com.<br /><searchLink fieldCode="AU" term="%22Wei+G%22">Wei G</searchLink>; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China. weiguo69@sohu.com.<br /><searchLink fieldCode="AU" term="%22Xu+GH%22">Xu GH</searchLink>; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China. xgh0913@hotmail.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101304009%22">Hepatology international</searchLink> [Hepatol Int] 2026 Apr; Vol. 20 (2), pp. 384-395. <i>Date of Electronic Publication: </i>2026 Feb 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101304009 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1936-0541 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219360533%22">19360533 </searchLink><i>NLM ISO Abbreviation: </i>Hepatol Int <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41703369
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s12072-026-11052-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 384
    Titles:
      – TitleFull: TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yang XG
      – PersonEntity:
          Name:
            NameFull: Deng LW
      – PersonEntity:
          Name:
            NameFull: Zhao Y
      – PersonEntity:
          Name:
            NameFull: Peng B
      – PersonEntity:
          Name:
            NameFull: Liu B
      – PersonEntity:
          Name:
            NameFull: Feng SF
      – PersonEntity:
          Name:
            NameFull: Liu DX
      – PersonEntity:
          Name:
            NameFull: Liu JF
      – PersonEntity:
          Name:
            NameFull: Sun YY
      – PersonEntity:
          Name:
            NameFull: Chen Y
      – PersonEntity:
          Name:
            NameFull: Liao CL
      – PersonEntity:
          Name:
            NameFull: Zhang C
      – PersonEntity:
          Name:
            NameFull: Liu L
      – PersonEntity:
          Name:
            NameFull: Cao L
      – PersonEntity:
          Name:
            NameFull: Ren Y
      – PersonEntity:
          Name:
            NameFull: Wei G
      – PersonEntity:
          Name:
            NameFull: Xu GH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2026 Apr
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1936-0541
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Hepatology international
              Type: main
ResultId 1